Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8623

14 FDA label images from Preferred Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)
Chemical structure of duloxetine hydrochloride, showing the molecular arrangement including fused aromatic rings, a thiophene ring, and side chain with a methylated amine group linked to a hydrochloride ion.*
FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)
A Kaplan-Meier estimator method chart showing the proportion of patients with relapse over time (days) for placebo and duloxetine treatments. The x-axis represents time from randomization to relapse (0 to 250 days), and the y-axis represents the proportion of patients with relapse (0.0 to 1.0). Duloxetine shows a lower relapse proportion compared to placebo throughout the timeline.*
FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)
A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time (days) from randomization between two treatments: placebo (dashed line) and duloxetine (solid line). The vertical axis represents the proportion of patients with relapse, and the horizontal axis shows time in days up to 300.*
FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)
A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, 60 mg QD, 20 mg QD, and placebo groups, illustrating patient improvement trends at various pain improvement levels.*
FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)
A line graph illustrating the percentage of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. The graph compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing trends in patient improvement across pain reduction percentages.*
FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)
A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and a placebo. The graph shows higher percentages of patient improvement with both Duloxetine regimens compared to placebo across different levels of pain improvement.*
FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two lines), and placebo. The y-axis represents the percentage of patients improved (0-100%), and the x-axis shows percent improvement in pain from baseline, ranging from >0 to 100%.*
FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)
A line graph titled 'Percentage of Pediatric Patients Aged 13 to 17 Years old with Juvenile Fibromyalgia Syndrome Achieving Various Levels of Pain Relief at week 12' compares duloxetine 60 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved, illustrating higher pain relief percentages in the duloxetine group across most improvement levels.*
FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The graph compares two groups: placebo and Duloxetine 60/120 mg once daily. The vertical axis represents the percentage of patients improved (0 to 100%), and the horizontal axis represents percent improvement in pain. The Duloxetine group shows generally higher percentages of improvement compared to placebo across the range.*
FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement categories from >0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. Two lines represent Duloxetine and placebo responses with Duloxetine consistently showing higher patient improvement rates.*
FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)
A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain in intervals from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines plot the data: one with diamonds representing Duloxetine and one with crosses representing placebo, showing Duloxetine generally leading to higher percentages of patient improvement across pain improvement levels.*
FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)
The image shows a blister pack containing ten delayed-release capsules of Duloxetine 60 mg. The capsules are arranged in a 2x5 layout. The packaging is from Preferred Pharmaceuticals Inc.*
FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)
Duloxetine 60 mg delayed-release capsules in a blister pack. The blister contains eight elongated capsules arranged in two vertical columns with four capsules each. The capsules are two-toned, with one half dark gray and the other half white.*
FDA Label Image

A Close-up Of A Yellow And Black Labelai-generated Content May Be Incorrect. (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 15)

A Close-up Of A Yellow And Black Labelai-generated Content May Be Incorrect. (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 15)
Label for Duloxetine Delayed-Release Capsules USP 60 mg, generic for Cymbalta, produced by Lupin Limited. The label includes dosage instructions in both English and Spanish, storage conditions, and a barcode. The capsules are described as blue and green, imprinted with LU Q03. The label also features the Preferred Pharmaceuticals, Inc. logo and cautions about federal law restrictions on drug transfer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.